NCT Number: NCT00208156
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this study is to allow patients who have already participated in an earlier 8 week study of Corlux versus placebo (an inactive pill) to receive additional courses of treatment with Corlux periodically if a psychotic episode should reappear during a period of one year.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Cnri, Llc, San Diego, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Completed participation through Day 56 in Corcept Therapeutics Protocol C-1073-07
- Are 18 to 75 years of age
- Have a diagnosis of major depressive disorder with psychotic features (DSM-IV 296.24 or 296.34)
- Are able to provide written informed consent
Exclusion criteria
- Have a major medical problem
- Have a history of an allergic reaction to Corlux (C-1073, mifepristone)
Treatment and study plan
Primary outcomes
-
To evaluate the safety and tolerability of Corlux (mifepristone) for the treatment of recurrent psychotic symptoms with major depression with psychotic features (PMD) who previously participated in Corcept Therapeutics Protocol C-1073-07
Secondary outcomes
-
To assess the frequency of retreatment with Corlux in patients with PMD and qualitatively describe the psychotic symptoms for which retreatment is clinically indicated
Sponsors and collaborators
Lead sponsor
Corcept Therapeutics
Industry
Registry information
Official study title
An Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Important dates
- Study start
- 2005
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- Sep 21, 2005
- Registry last updated
- Feb 15, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Clinical and Biological Characteristics of Psychotic Depression
NCT00576095
Behavior, Behavioral Symptoms
Stanford, California, United States
View Trial DetailsPsychiatric Genotype/Phenotype Project Repository
NCT00762866
Behavior, Behavioral Symptoms
Nashville, Tennessee, United States
View Trial DetailsIndividualized Functional Connectivity Targeting in aiTBS for Depression
NCT05680727
Behavior, Behavioral Symptoms
Boston, Massachusetts, United States
View Trial DetailsA Study of Psilocybin for Major Depressive Disorder (MDD)
NCT03866174
Behavior, Behavioral Symptoms
San Francisco, California, United States
View Trial Details